Cargando…

Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy

STUDY OBJECTIVES: Evaluate efficacy and safety of lower-sodium oxybate (LXB), a novel oxybate medication with 92% less sodium than sodium oxybate (SXB). METHODS: Adults aged 18–70 years with narcolepsy with cataplexy were eligible. The study included a ≤30-day screening period; a 12-week, open-label...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bogan, Richard K, Thorpy, Michael J, Dauvilliers, Yves, Partinen, Markku, Del Rio Villegas, Rafael, Foldvary-Schaefer, Nancy, Skowronski, Roman, Tang, Lihua, Skobieranda, Franck, Šonka, Karel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neurological Disorders
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953213/ https://www.ncbi.nlm.nih.gov/pubmed/33184650 http://dx.doi.org/10.1093/sleep/zsaa206

Ejemplares similares

Corrigendum to: Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Corrigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, Double-Blind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy
por: Bogan, Richard K, et al.
Publicado: (2021)

Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Correction to: Changes in Cataplexy Frequency in a Clinical Trial of Lower‑Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications
por: Dauvilliers, Yves, et al.
Publicado: (2022)

Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy
por: Bogan, Richard K., et al.
Publicado: (2023)

Psychosis in Patients with Narcolepsy as an Adverse Effect of Sodium Oxybate
por: Sarkanen, Tomi, et al.
Publicado: (2014)

Efficacy of once-nightly sodium oxybate (FT218) in narcolepsy type 1 and type 2: post hoc analysis from the Phase 3 REST-ON Trial
por: Dauvilliers, Yves, et al.
Publicado: (2023)

Sleep, Narcolepsy, and Sodium Oxybate
por: Mamelak, Mortimer
Publicado: (2022)

Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy
por: Kushida, Clete A, et al.
Publicado: (2021)

Safety and efficacy of long-term use of sodium oxybate for narcolepsy with cataplexy in routine clinical practice
por: Drakatos, Panagis, et al.
Publicado: (2017)

Population and Noncompartmental Pharmacokinetics of Sodium Oxybate Support Weight‐Based Dosing in Children and Adolescents With Narcolepsy With Cataplexy
por: Chen, Cuiping, et al.
Publicado: (2020)

Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate
por: Schneider, Logan D, et al.
Publicado: (2023)

Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia
por: Thorpy, Michael J, et al.
Publicado: (2022)

Off-label Sodium Oxybate in Childhood Narcolepsy: A Comprehensive Report
por: Miskoff, Jeffrey A, et al.
Publicado: (2018)

Effect of FT218, a Once-Nightly Sodium Oxybate Formulation, on Disrupted Nighttime Sleep in Patients with Narcolepsy: Results from the Randomized Phase III REST-ON Trial
por: Roth, Thomas, et al.
Publicado: (2022)

Sodium oxybate in treatment-resistant rapid-eye-movement sleep behavior disorder
por: During, Emmanuel H, et al.
Publicado: (2023)

A Case of Off-label Sodium Oxybate in an 11-Year-Old with Narcolepsy
por: Miskoff, Jeffrey A, et al.
Publicado: (2019)

Clinician Preferences for Oxybate Treatment for Narcolepsy: Survey and Discrete Choice Experiment
por: Morse, Anne Marie, et al.
Publicado: (2023)

Once-nightly sodium oxybate (FT218) in the treatment of narcolepsy: a letter to the editor commenting on the recent publication by C. Kushida et al
por: Skobieranda, Franck, et al.
Publicado: (2022)

Sodium Oxybate: a Substitute for Alcohol?
por: Gual, A., et al.
Publicado: (2022)

Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1
por: Schinkelshoek, Mink S., et al.
Publicado: (2018)

REM Sleep Behavior Disorder in Children With Type 1 Narcolepsy Treated With Sodium Oxybate
por: Antelmi, Elena, et al.
Publicado: (2021)

Preferences for Attributes of Sodium Oxybate Treatment: A Discrete Choice Experiment in Patients with Narcolepsy
por: Dubow, Jordan, et al.
Publicado: (2022)

O024 Sodium oxybate for refractory narcolepsy and idiopathic hypersomnia: clinical and employment outcomes
por: Hernest, A, et al.
Publicado: (2023)

Clinical perspective: monitoring sodium oxybate-treated narcolepsy patients for the development of sleep-disordered breathing
por: Feldman, Neil T.
Publicado: (2009)

Resolution of Sleepwalking Behavior after Initiation of Sodium Oxybate in a Patient with Narcolepsy Type 2
por: Hesselbacher, Sean, et al.
Publicado: (2018)

Evaluation of Quality of Life in Patients With Narcolepsy Treated With Sodium Oxybate: Use of the 36-Item Short-Form Health Survey in a Clinical Trial
por: Bogan, Richard, et al.
Publicado: (2016)

Sodium oxybate—a new horizon for symptomatic treatment of RBD?
por: Stefani, Ambra, et al.
Publicado: (2023)

Long-term follow-up on the effects of sodium oxybate on daytime sleepiness and sleep architecture in patients with narcolepsy type 1
por: Peraita-Adrados, Rosa, et al.
Publicado: (2023)

Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea
por: Malhotra, Atul, et al.
Publicado: (2019)

The Xyrem(®) (Sodium Oxybate) Risk Evaluation and Mitigation Strategy (REMS) Program in the USA: Results From 2016 to 2017
por: Strunc, Michael J., et al.
Publicado: (2021)

Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union
por: Iranzo, Alex, et al.
Publicado: (2020)

Clinical and polysomnographic course of childhood narcolepsy with cataplexy
por: Pizza, Fabio, et al.
Publicado: (2013)

Pharmacokinetics, bioavailability, and bioequivalence of lower‐sodium oxybate in healthy participants in two open‐label, randomized, crossover studies
por: Chen, Cuiping, et al.
Publicado: (2021)

Long-term Effect of Sodium Oxybate (Xyrem®) in Spasmodic Dysphonia with Vocal Tremor
por: Simonyan, Kristina, et al.
Publicado: (2013)

Individualized Treatment Patterns for Patients with Narcolepsy Treated with Oxybate: A Clinical Practice Perspective
por: Roy, Asim, et al.
Publicado: (2023)

Correlation of Changes in Patient-Reported Quality of Life With Physician-Rated Global Impression of Change in Patients With Narcolepsy Participating in a Clinical Trial of Sodium Oxybate: A Post Hoc Analysis
por: Bogan, Richard K., et al.
Publicado: (2017)

A Brief Up-Date of the Use of Sodium Oxybate for the Treatment of Alcohol Use Disorder
por: Caputo, Fabio, et al.
Publicado: (2016)

Increasing Evidence for the Use of Sodium Oxybate in Multi-Drug-Resistant Lance–Adams Syndrome
por: Riboldi, Giulietta M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_doav3ctj4nf9subv9heqf45lh8